Ask VialBase
growth · hormone

CJC-1295

Also known as: CJC-1295 DAC, CJC-1295 no DAC, Mod GRF 1-29, Modified GRF(1-29), Tetrasubstituted GRF(1-29)
FDA: Not FDA-approved WADA: Prohibited

CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) — the endogenous 44-amino-acid hypothalamic peptide that signals the anterior pituitary to release growth hormone. CJC-1295 uses four amino acid substitutions to resist enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), dramatically extending its half-life compared to native GHRH. Two forms exist: - CJC-1295 no DAC (Mod GRF 1-29) — Short-acting (~30 min half-life), produces discrete GH pulses. Preferred for mimicking natural GH physiology. - CJC-1295 with DAC — Drug Affinity Complex covalently binds to albumin, extending half-life to ~8 days. Produces sustained GH elevation rather than pulsatile release. Almost always

This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.

Molecular weight 3,367.97 Da
Half-life ~30 min no
CAS number —
Route Subcutaneous
02

Mechanism

Growth hormone releasing hormone (GHRH) analog — binds GHRH receptors on anterior pituitary somatotrophs, stimulating endogenous GH synthesis and pulsatile release

03

Dosing

DOSE RANGE 100–300 mcg
FREQUENCY 1-3x daily (no DAC) / 2x weekly (DAC)
CYCLE LENGTH 8-12 weeks

Usually stacked with Ipamorelin for synergistic GH release. Best dosed before bed or post-workout.

04

Research summary

Study Type Year Key Finding
Molecular signaling of therapeutic peptides in orthopaedic medicine — PI3K/Akt, mTOR, MAPK, TGF-β, AMPK pathways Review 2026 Growth hormone secretagogues (CJC-1295, ipamorelin) activate IGF-1 signaling
Therapeutic peptides in orthopaedic injuries — narrative review of BPC-157, TB-500, CJC-1295 + Ipamorelin, Tesamorelin, GHK-Cu Narrative review 2026 CJC-1295 + ipamorelin activate IGF-1 signaling and satellite cell repair
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review Critical review 2026 CJC-1295 identified among most popular GH-releasing peptides in sport
Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy older adults clinical trial 2006 GHRH analog increased GH pulse amplitude in older adults
Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults clinical trial 2006 Single dose of CJC-1295 DAC elevated GH and IGF-1 for 6-14 days
Synergistic effects of GHRH and GHRP on GH release in humans clinical trial 2004 GHRH + GHRP combination produces synergistic GH release
Growth hormone-releasing hormone analogs: chemistry and pharmacology review 2006 Reviews GHRH analog development including CJC-1295
05

Stacking & interactions

GHRH + GHRP synergy for amplified GH pulse

GH-mediated recovery amplification for injury healing

Comprehensive healing — GH elevation + targeted tissue repair

Stacks containing CJC-1295

Anabolic Growth

CJC-1295 (w/ DAC) + Ipamorelin + IGF-1 LR3

Bone Density Builder

CJC-1295 + Ipamorelin + GHK-Cu

GH-Boost Metabolic

CJC-1295 (w/ DAC) + Ipamorelin + AOD-9604

HPTA Reboot

Kisspeptin-10 + Gonadotropin + CJC-1295 + Ipamorelin

Spartan

CJC-1295 + Ipamorelin + IGF-1 LR3 + BPC-157

T-Boost & GH Sync

Kisspeptin-10 + CJC-1295 + Ipamorelin + IGF-1 LR3 (low dose)

28-day resets featuring CJC-1295

06

Sourcing

Current prices

Updated today

5mg

10mg

Only vendor stocking this size on the VialBase roster.

Size unspecified

Stocks this compound Third-party tested Public COAs Positive rep

Save 20% with code VIALBASE at checkout

Stocks this compound Third-party tested Public COAs Positive rep

Save 15% with code VIALBASE at checkout

Stocks this compound Third-party tested Public COAs Positive rep

VialBase may earn a commission on purchases through partner links — never at additional cost to you. Full disclosure.

Also vetted at
What bloodwork do I need?

Reference ranges are general guidelines. Consult your physician for interpretation.

PRE-CYCLE
  • IGF-1
  • Fasting Glucose
  • Fasting Insulin
  • HbA1c
  • CMP
  • CBC
  • Lipid Panel
DURING CYCLE
  • IGF-1
  • Fasting Glucose
  • Fasting Insulin
POST-CYCLE
  • IGF-1
  • Fasting Glucose
  • Lipid Panel
Safety & Regulatory Status
FDA STATUS Not FDA-approved. Category 2 (under evaluation for 503A compounding)
WADA STATUS Prohibited (S2 — peptide hormones, growth factors, and related substances)

Regulatory status for CJC-1295 may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.

References

  1. Various. Molecular signaling of therapeutic peptides in orthopaedic medicine — PI3K/Akt, mTOR, MAPK, TGF-β, AMPK pathways. Orthopaedic Review (2026). PMID: 41476424
  2. Various. Therapeutic peptides in orthopaedic injuries — narrative review of BPC-157, TB-500, CJC-1295 + Ipamorelin, Tesamorelin, GHK-Cu. Orthopaedic Review (2026). PMID: 41490200
  3. Coutinho LFD, DE Oliveira Neves LF, Camilo RP. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. Journal of Sports Medicine and Physical Fitness (2026). PMID: 41880199
  4. Ionescu, M., Frohman, L.A.. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy older adults. Journal of Clinical Endocrinology and Metabolism (2006). PMID: 16608888
  5. Teichman, S.L., Neale, A., Lawrence, B. et al.. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology and Metabolism (2006). PMID: 16352683
  6. Bowers, C.Y., Granda, R., Mohan, S. et al.. Synergistic effects of GHRH and GHRP on GH release in humans. Journal of Clinical Endocrinology and Metabolism (2004). PMID: 15181020
  7. Alba, M., Fintini, D., Sagazio, A. et al.. Growth hormone-releasing hormone analogs: chemistry and pharmacology. Growth Hormone & IGF Research (2006). PMID: 16300975